

Vutrisiran Biochemical

Vutrisiran

CATALOG #
AAA227963


PRODUCT SYNONYMS

Vutrisiran; Vutrisiran biochemical


PRODUCT SPECIFICATIONS

Purity/Purification	98%
CAS	1867157-35-4
Solubility	<1mg/ml refers to the product slightly soluble or insoluble
In vitro	In non-human primates, single SC doses of Vutrisiran 0.3 and 1 mg/kg achieved mean maximum TTR reductions (nadirs) of 55% and 96%, respectively, with serum TTR reductions persisting beyond 4 months for the 1 mg/kg dose. In the same study, monthly doses of 1 and 3mg/kg maintained a reduction of TTR levels at 96%, relative to baseline[1].
Preparation and Storage	Powder: -20 degree C for 3 years In solvent: -80 degree C for 2 years

IMAGES



Structure
CH₂COOH-PEG₉-CH₂COOH, CAS 2250056-46-1



Structure
CH₂COOH-PEG₉-CH₂COOH, CAS 2250056-46-1

ADDITIONAL INFORMATION

Related Product Information for Vutrisiran biochemical	Vutrisiran (ALN-TTRsc02) is a liver-directed, investigational, small interfering ribonucleic acid (siRNA) agent. Vutrisiran can be used for transthyretin (TTR)-mediated amyloidosis research.
References	1. An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Small volumes of product may become entrapped in the seal of the vial during shipment and storage; if necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the cap.